Literature DB >> 24803022

MiR-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1.

Guoxing Xu1, Jin Wang, Yixin Jia, Feng Shen, Wensheng Han, Yifan Kang.   

Abstract

BACKGROUND/AIMS: Mounting evidence has shown that aberrant expression of miRNAs correlates with human cancers, and that miRNAs can function as tumor suppressors or oncogenes. Here, we investigated the role and mechanism of miR-142-3p in human osteosarcoma.
METHODS: We used quantitative real-time RT-PCR to measure the expression of miR-142-3p in human osteosarcoma cell lines and tissues. The roles of miR-142-3p in osteosarcoma development were studied using cultured HOS, MG63 and Saos-2 cells and tumor xenograft analyses in nude mice; their target genes were also investigated.
RESULTS: We found that miR-142-3p was significantly downregulated in osteosarcoma cell lines and clinical specimens. Overexpression of miR-142-3p suppressed osteosarcoma cell proliferation, migration and invasion, whereas miR-142-3p knockdown increased these parameters. The xenograft mouse model also revealed the suppressive effect of miR-142-3p on tumor growth. High mobility group AT-hook 1 (HMGA1) was identified as a target of miR-142-3p. Downregulation of HMGA1 induced effects on osteosarcoma cell lines similar to those induced by miR-142-3p. In contrast, restoration of HMGA1 abrogated the effects induced by miR-142-3p up-regulation.
CONCLUSION: These results indicated that miR-142-3p may function as a tumor suppressor by targeting HMGA1 in osteosarcoma.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24803022     DOI: 10.1159/000358700

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  23 in total

1.  Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion.

Authors:  Qiang Xiao; Yu Yang; Xuepu Zhang; Qing An
Journal:  Tumour Biol       Date:  2015-12-01

Review 2.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

3.  Downregulation of microRNA-142-3p and its tumor suppressor role in gastric cancer.

Authors:  Yi Wang; Zhidong Cao; Lanlan Wang; Siqi Liu; Jianqiang Cai
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

4.  Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis.

Authors:  Audrey Villard; Lucien Marchand; Charles Thivolet; Sophie Rome
Journal:  J Mol Biomark Diagn       Date:  2015-10-02

5.  Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression.

Authors:  Biyong Deng; Bing Qiu
Journal:  Tumour Biol       Date:  2015-06-24

6.  Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3.

Authors:  Yunlong Bi; Yu Jing; Yang Cao
Journal:  Tumour Biol       Date:  2015-05-29

7.  Exosomal miR-142-3p secreted by hepatitis B virus (HBV)-hepatocellular carcinoma (HCC) cells promotes ferroptosis of M1-type macrophages through SLC3A2 and the mechanism of HCC progression.

Authors:  Zongqiang Hu; Yanfeng Yin; Jie Jiang; Chuntao Yan; Yiting Wang; Dongdong Wang; Li Li
Journal:  J Gastrointest Oncol       Date:  2022-04

8.  MicroRNA-142-3p inhibits proliferation and induces apoptosis by targeting the high-mobility group box 1 via the Wnt/β-catenin signaling pathway in glioma.

Authors:  Chong Li; Shiyu Feng; Ling Chen
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

9.  An integrated approach to reveal miRNAs' impacts on the functional consequence of copy number alterations in cancer.

Authors:  Kening Li; Yongjing Liu; Yuanshuai Zhou; Rui Zhang; Ning Zhao; Zichuang Yan; Qiang Zhang; Shujuan Zhang; Fujun Qiu; Yan Xu
Journal:  Sci Rep       Date:  2015-06-23       Impact factor: 4.379

10.  LncRNA TTN-AS1 acts as a tumor promoter in gallbladder carcinoma by regulating miR-107/HMGA1 axis.

Authors:  Zhaoxia Lin; Yaosheng Li; Rongfeng Shao; Yuqing Hu; Han Gao
Journal:  World J Surg Oncol       Date:  2021-06-05       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.